A survey of 158 CEOs and 216 venture capital firms revealed a large gap between the chief executives’ wish list for potential backers and what VCs think the CEOs want.
Startup CEOs in the IT and life science industries want VCs who are "entrepreneur friendly" and "collaborative" without being too hands-on in their approach, according to a survey sponsored by the National Venture Capital Assn.
And proximity trumps reach when it comes to location, with CEOs preferring VC shops with a presence in their area to VCs with bureaus around the globe, according to the survey.
Gender matters too, with the CEO respondents, with 25% saying the gender balance among VC firms’ partners counts but only 10% of VCs citing gender balance as a factor.
"There is a gap between what CEOs are looking for in a VC firm and what VC firms believe CEOs want," according to the survey. "CEOs place great weight on what their peers and third parties say and think about your firm."
Healthcare deals slide during H1 2013, but value rises 25%
There were 20.7% fewer merger & acquisition deals in the healthcare sector during the 1st half of the year, according to the Berkery Noyes investment bank, but the value of those deals rose 25% compared with H1 2012.
There were 157 deals worth a cumulative $8.0 billion during the 6 months ended June 1, compared with 198 deals worth $6.4 billion during the same period last year, according to the bank.
Hansen, MiMedx release Q2 prelims
Hansen Medical (NSDQ:HNSN) shares were down more than 11% today after the robotic surgery company cut its sales forecast for the 2nd quarter, saying it expects revenues of $3.1 million to $3.4 million in the second quarter, down 4% to 12%. HNSN shares were trading at $1.25 apiece as of about 3:10 p.m. today, down 11.4%.
Biosense Technologies looks to crowd-fund its smartphone urinalysis system
Mountain View, California-based Biosense Technologies, maker of the uChek Universal smartphone-enabled urine analysis system, plans to crowdfund the device ahead of seeking 510(k) clearance from the FDA.
CAS Medical closes $6M round
CAS Medical Systems (NSDQ:CASM) said it will clear about $5.9 million from an offering of 5.2 million shares that closed yesterday. The shares went for $1.25 apiece, including a bloc of 3.2 million shares acquired by Deerfield Capital Management entities and Deerfield founder James Flynn.
- Bruker Corp. (NSDQ:BRKR): Cowen & Co. initiates coverage with “outperform” rating
- Cyberonics (NSDQ:CYBX): Zacks downgrades from “outperform” to “neutral” rating, $55 price target
- Edwards Lifesciences (NYSE:EW): Leerink Swann lowers price target to $80 from $85, maintains "outperform" rating.
- Mallinckrodt plc (NYSE: MNK): Leerink Swann initiates coverage with “market perform” rating.
- Philips (NYSE:PHG): JP Morgan Cazenove upgrades from “neutral” to “outperform” rating; JPMorgan Chase & Co. upgrades from “neutral” to “overweight” rating.
- Stryker (NYSE:SYK): Citigroup reiterates "neutral" rating, raises price target from $72 to $78; Leerink Swann reiterates "outperform" rating, lifts price target to $79 from $74.